Related Experiment Video
Updated: Jun 6, 2025
Ileectomy-induced Bile Overaccumulation in Mouse Intestine
Published on: August 21, 2017
Delayed-Onset Isolated ICI (pembrolizumab)-Associated Gastritis with Concomitant Intussusception
Casey Reed1, Yousef Elfanagely2, May Min2
1Department of Internal Medicine, Warren Alpert Medical School of Brown University, Providence, RI.
Immune checkpoint inhibitors can cause immune-related adverse events. This case highlights an uncommon presentation of isolated gastritis and intussusception linked to pembrolizumab therapy.
Area of Science:
- Oncology
- Immunology
Background:
- Immune checkpoint inhibitors (ICIs) are crucial in cancer therapy.
- Immune-related adverse events (irAEs) are common side effects of ICIs.
- Gastrointestinal irAEs are frequent, but isolated gastritis is rare.
Observation:
- A patient developed isolated gastritis.
- The gastritis was associated with intussusception.
- Pembrolizumab, an anti-programmed cell death-1 antibody, was administered.
Findings:
- This case presents a rare instance of isolated ICI-related gastritis.
- The gastritis occurred concurrently with intussusception.
- Pembrolizumab therapy was implicated in these events.
Implications:
- Clinicians should consider rare irAEs like isolated gastritis.
- This case expands the known spectrum of ICI-induced gastrointestinal toxicity.
- Further research may elucidate mechanisms of ICI-related gastritis and intussusception.
More Related Videos
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
05:16Laparoscopy-endoscopy Cooperative Surgery for the Treatment of Gastric Gastrointestinal Stromal Tumors
Published on: February 19, 2022
Related Concept Videos
01:21Drugs for Treatment of Constipation-Predominant IBS
01:23Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
01:30Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...